A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

Inclusion Criteria:

• Participant must have ongoing participation in an etavopivat parent study fortreatment of sickle cell disease (SCD) or thalassaemia and have completed at least atreatment period of the parent study.

• Participant must have derived clinical benefit from treatment with etavopivat, asdetermined by the investigator.

• Any participant with dose reduction or temporary discontinuation will need to besuccessfully rechallenged to the full dose of etavopivat before transferring.

• Participants on hydroxyurea (HU), crizanlizumab or l-glutamine oral powder (Endari®)treatment at the time of consent may be eligible if they have been on a stable dosein the parent study as defined at the investigator's discretion. Necessaryadjustments related to weight or age are accepted. Participants with temporary dosereductions or pauses due to medical reasons may still be considered to have a stabledose, as determined by the investigator, who will assess the impact of theseadjustments based on clinical context and the participant's overall health status.

Exclusion Criteria:

• Any disorder, except for conditions associated with SCD or thalassaemia, which inthe investigator's opinion might jeopardise participant's safety or compliance withthe protocol.

• Participant withdrew or had permanent treatment discontinuation from an etavopivatclinical study.

• Participants on permanent dose reduction (greater than [>] 28 days or more) orongoing temporary treatment discontinuation.

• Use of any of the following within the timeframes prior to the transfer visit asstated:

• Use of haemoglobin S (HbS) polymerisation inhibitors within participation of theparent study or anticipated need for this agent during this study.

• Use of an experimental selectin antagonist (e.g., monoclonal antibody or smallmolecule) within the parent study or anticipated need for such agents during thisstudy.

• Use of erythropoietin or other haematopoietic growth factor treatment for more than 4 consecutive weeks during the parent study or anticipated need of such agents for amaintenance treatment during this study.

• Receiving or use of concomitant medications that are strong inducers of cytochromeP450 (CYP) 3A4 within 2 weeks of the transfer visit or anticipated need for suchagents during the study.

• Current participation in a study that is not a designated parent study, or plannedparticipation in any other clinical study, for the duration of FLORAL.